FMP

FMP

Enter

GMDA - Gamida Cell Ltd.

Financial Summary of Gamida Cell Ltd.(GMDA), Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood

photo-url-https://financialmodelingprep.com/image-stock/GMDA.png

Gamida Cell Ltd.

GMDA

NASDAQ

Inactive Equity

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

0.0327 USD

-0.0073 (-22.32%)

About

ceo

Ms. Abigail L. Jenkins

sector

Healthcare

industry

Biotechnology

website

https://www.gamida-cell.com

exchange

NASDAQ

Description

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to trea...

CIK

0001600847

ISIN

IL0011552663

CUSIP

M47364100

Address

5 Nahum Heftsadie Street

Phone

972 2 659 5666

Country

IL

Employee

143

IPO Date

Oct 26, 2018

Summary

CIK

0001600847

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

M47364100

ISIN

IL0011552663

Country

IL

Price

0.03

Beta

1.03

Volume Avg.

9.38M

Market Cap

4.34M

Shares

-

52-Week

0.03-2.51

DCF

-0.03

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.04

P/B

-

Website

https://www.gamida-cell.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest GMDA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep